EyeCon 2026 Banner
|Articles|September 15, 2004

FDA advisory group likes Macugen but delays formal vote for now

New York-Members of the FDA's advisory committee reviewing pegaptanib sodium injection (Macugen) for the treatment of neovascular age-related macular degeneration say they are "impressed" with the drug but declined to take a formal vote.


Latest CME